scholarly journals A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative

Hepatology ◽  
2005 ◽  
Vol 42 (1) ◽  
pp. 77-85 ◽  
Author(s):  
Vassiliki-Anastasia Sypsa ◽  
Konstantinos Mimidis ◽  
Nicholas C. Tassopoulos ◽  
Dimitrios Chrysagis ◽  
Themistoklis Vassiliadis ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Kinetic Study ◽  
Chronic Hepatitis B ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Viral Kinetic ◽  
Pegylated Interferon Alfa

scholarly journals Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study

2013 ◽  
Vol 13 (11) ◽  
Author(s):  
Meisam Mahdavi ◽  
Houshang Amirrasouli ◽  
Seyed Moayed Alavian ◽  
Bita Behnava ◽  
Faranak Kazerouni ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Pegylated Interferon Alfa ◽  
Preliminary Study

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

The Lancet ◽  
2005 ◽  
Vol 365 (9454) ◽  
pp. 123-129 ◽  
Author(s):  
Harry LA Janssen ◽  
Monika van Zonneveld ◽  
Hakan Senturk ◽  
Stefan Zeuzem ◽  
Ulus S Akarca ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Randomised Trial ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Positive Chronic Hepatitis ◽  
Pegylated Interferon Alfa

scholarly journals Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B

2011 ◽  
Vol 10 (1) ◽  
pp. 84-87 ◽  
Author(s):  
Mangano Carmelo ◽  
Squadrito Giovanni ◽  
Cacciola Irene ◽  
Carpentieri Mariastella ◽  
Foti Giuseppe ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Treated Patient ◽  
Pegylated Interferon ◽  
Interferon Alfa ◽  
Pegylated Interferon Alfa

Interferon versus direct antiviral therapy in patients with chronic hepatitis B

2011 ◽  
Vol 152 (22) ◽  
pp. 869-874 ◽  
Author(s):  
István Tornai
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Pegylated Interferon ◽  
Antiviral Effect ◽  
Interferon Alfa ◽  
First Line ◽  
Nucleotide Analogue ◽  
Pegylated Interferon Alfa

Treatment of chronic hepatitis B is still challenging. Lots of parameters are needed to be considered before and during the therapy. There are several possible endpoints and their durability is very much variable. Patients with HBeAg-positive and HBeAg-negative hepatitis B need treatment. Two different strategies are available. Interferon-based therapy is a limited treatment, which might result in a sustained immune response in about one third of the patients, leading to an induced remission, sometimes years after the end of the treatment. According to the other strategy a continuous, indefinite oral nucleoside/nucleotide analogue (NA) treatment is administered to maintain a remission. However, relapse is rather frequent after the cessation of this therapy. During the long-term NA treatment drug resistance can lead to the loss of antiviral effect. Three first-line drugs are recommended, pegylated interferon alfa-2a, entecavir and tenofovir. If there is no contraindication to interferon, it is worth trying to achieve immune control and an induced remission. In patients, who do not respond to interferon, a sequential NA therapy is indicated. Orv. Hetil., 2011, 152, 869–874.

Sign in / Sign up

Export Citation Format

Share Document